Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.60 |
| ▸ | PER2 | O15055 | 8/20 | 0.39 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357524 | 0.81 | CHRM2 (0.57) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL17946144 | 0.77 | — | — | |
| SCHEMBL2379257 | 0.77 | — | — | |
| SCHEMBL13232148 | 0.75 | — | — | |
| SCHEMBL11463019 | 0.75 | — | — | |
| SCHEMBL11288962 | 0.75 | — | — | |
| SCHEMBL11479479 | 0.75 | — | — | |
| SCHEMBL13232234 | 0.75 | — | — | |
| SCHEMBL4330615 | 0.73 | CHRM2 (0.49) | CHRM2CHRM4CHRM1CHRM3CHRM5 | |
| SCHEMBL4338414 | 0.72 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735603-B2 | N-substituted pyrrolidonium ionic liquids with expanded linker | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120130088-A1 | N-Substituted Pyrrolidonium Ionic Liquids with Expanded Linker | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130088-A1 | N-Substituted Pyrrolidonium Ionic Liquids with Expanded Linker | NUP205, SLC7A5, NUP50 | CHRM2 4314/4885CHRM4 3298/4885CHRM1 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.